This article was originally published May 17.
Belgian genomic service provider DNAVision said this week that it is purchasing an Illumina HiScanSQ microarray scanning and sequencing instrument for its Gosselies facility.
The company plans to use the new instrument initially for genome-wide association studies for its pharmaceutical and medical research customers.
The new platform, which DNAVision said will be the first HiScanSQ for commercial use in Europe, will add to the firm's existing next-gen sequencing services on the Illumina HiSeq 2000, Illumina GAIIx, and Roche 454 GS FLX, and to its array services using Illumina, Agilent, and Affymetrix microarrays.
DNAVision is ISO17025-accredited, CLIA-certified, CAP-accredited, GLP-certified, and GMP-certified.